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Objective: We assessed the spatiotemporal GLP-1 and GIP receptor signaling, trafficking, and recycling dynamics of GIPR mono-agonists, GLP-
1R mono-agonists including semaglutide, and GLP-1/GIP dual-agonists MAR709 and tirzepatide.
Methods: Receptor G protein recruitment and internalization/trafficking dynamics were assessed using bioluminescence resonance energy
transfer (BRET)-based technology and live-cell HILO microscopy.
Results: Relative to native and acylated GLP-1 agonists, MAR709 and tirzepatide showed preserved maximal cAMP production despite partial
Gas recruitment paralleled by diminished ligand-induced receptor internalization at both target receptors. Despite MAR709’s lower internalization
rate, GLP-1R co-localization with Rab11-associated recycling endosomes was not different between MAR709 and GLP-1R specific mono-
agonists.
Conclusions: Our data indicated that MAR709 and tirzepatide induce unique spatiotemporal GLP-1 and GIP receptor signaling, trafficking, and
recycling dynamics relative to native peptides, semaglutide, and matched mono-agonist controls. These findings support the hypothesis that the
structure of GLP-1/GIP dual-agonists confer a biased agonism that, in addition to its influence on intracellular signaling, uniquely modulates
receptor trafficking.
 2021 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Glucagon-like peptide-1 (GLP-1) is a pleiotropic hormone with broad
pharmacological potential due to its ability to improve body weight,
food intake, and glucose metabolism [1]. However, active GLP-1,
which is primarily GLP-1 (7e36 amide) and to a lower extent GLP-1
(7e37), is subject to rapid proteolytic degradation and fast renal
elimination [2e5]. Long-acting analogs with biochemical modifications
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Despite molecular enhancements in time action, dose-dependent
adverse effects limit the maximal efficacy and overall therapeutic
potential of GLP-1R mono-agonists [8]. Single chimeric molecules with
dual agonism at the receptors for GLP-1 and glucose-dependent
insulinotropic polypeptide (GIP) improve body weight and glucose
handling with superior potency to GLP-1R mono-agonists in preclinical
[9,10] and clinical studies [11]. While GLP-1/GIP dual-agonists have
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Original Articlecontribution of GIPR agonism to these applications is questionable.
Mice with GIP receptor (GIPR) depletion are protected from diet-
induced obesity [12], and patients with type 2 diabetes show an
impaired insulinotropic response to GIP infusion [13]. Antibodies
antagonizing GIPR improve body weight and glucose metabolism in
obese rodents and non-human primates [14]. Recent hypotheses to
reconcile these discrepancies include GIPR agonists acting as func-
tional GIPR antagonists, or alternatively that specific ligands engage
unique receptor signaling, trafficking, and/or recycling dynamics,
commonly referred to as biased-agonism [15]. Biased agonism at the
GLP-1R has been linked to differential cellular desensitization capac-
ities via differences in receptor internalization and/or b-arrestin
recruitment, as has been shown for Phe1-substituted exendin-4 [16].
In addition to the GLP-1R agonists exendin-4 and oxyntomodulin, both
of which demonstrate bias toward b-arrestin recruitment [17], a/b
amino acid modifications to the GLP-1 backbone sequence can also
result in differential GLP-1R signaling [18]. Likewise, the GLP-1/GIP
dual-agonist tirzepatide (LY3298176; Eli Lilly, Indianapolis, IN, USA)
was recently reported to favor phosphorylation of ERK1/2 relative to b-
arrestin and Gas protein at both target receptors [19].
The aim of this study was to assess the spatiotemporal GLP-1 and GIP
receptor signaling, trafficking, and recycling dynamics mediated by
select GLP-1R and GIPR mono- and dual-agonists. MAR709 is char-
acterized as a balanced GLP-1/GIP co-agonist and is acylated with a
C16 fatty mono-acid, which allows for once-daily time action in
humans [20,21]. Tirzepatide is characterized as an imbalanced GLP-1/
GIP co-agonist that favors GIPR potency and is acylated with a C20
fatty di-acid at position 20, which allows for once-weekly time action in
humans [22]. Our results show that both dual-agonists, MAR709 and
tirzepatide, act as partial effectors at GLP-1R for G protein recruitment,
receptor internalization, b-arrestin recruitment, Rab5þ/Rab7þ recep-
tor trafficking, and endosomal G-protein recruitment, while retaining
full-agonist capacity for cAMP production. Interestingly, despite
showing a reduced receptor internalization rate, MAR709 acts as a full
effector for stimulating GLP-1R incorporation into Rab11þ recycling
endosomes. At the GIP receptor, dual-agonists similarly act as full
agonists for cAMP, but lack the G protein recruitment partial agonism
profile and display limited receptor internalization and trafficking
properties. Our data support the hypothesis that biased agonism with
unique receptor signaling and trafficking properties might be a po-




Untagged human GLP-1R was purchased from Sino Biological Inc. (Cat
#: HG13944-UT, Beijing, China) and untagged human GIPR and human
GIPR-turbo GFP were purchased from OriGene Technologies Inc. (Cat #:
SC110906 and RG210811, Rockville, MD, USA). Human GLP-1R-GFP
was a gift from Professor David Hodson (University of Birmingham,
Birmingham, UK). Human GLP-1R-Rluc8 (hGLP-1R-Rluc8) was a gift
from Professor Patrick Sexton (Monash University, Melbourne, Australia).
Human CMV-GIPR-Rluc8 (hGIPR-Rluc8) with VSLGSSG residues was
constructed and purchased from VectorBuilders Inc. (Neu-Isenburg,
Germany). cAMP sensor pcDNA3L-His-CAMYEL (ATCC MBA-277TM)
was purchased from ATCC (Manassas, VA, USA) [23]. NES-Nluc-mini-
G plasmids (Gas, Gaq, Gai, and Ga12/13) and subcellular/endosomal
markers Rab GTPases (Rabs) Venus-Rab5a (early endosomes), Venus-
Rab7a (late endosomes/lysosomes), Venus-Rab11a (recycling endo-
somes), and Venus-KRAS (plasma membrane) were gifts from Kevin2 MOLECULAR METABOLISM 49 (2021) 101181  2021 The Authors. Published by Elsevier GPfleger (Harry Perkins Institute of Medical Research, Nedlands, WA,
Australia) as originally published by Professor Nevin Lambert (Augusta
University, Augusta, GA, USA) [24]. b-arrestin 1/2-Rluc8 plasmids were
a gift from Professor Terry Hébert (McGill University, Montreal, Canada).
2.2. Peptide synthesis
Semaglutide was provided by Novo Nordisk (Bagsværd, Denmark). All
of the other peptides were prepared via standard automated Fmoc/tBu
solid-phase peptide synthesis on Rink Amide ChemMatrix resin. An
orthogonal protecting group strategy was used to incorporate the
protraction moiety onto the appropriate lysine side chain. Following
synthesis, crude compounds were cleaved from the resin with
95:2.5:2.5 trifluoroacetic acid/water/triisopropylsilane. The crude
compounds were purified by reversed-phase high-performance liquid
chromatography (RP-HPLC) on a Luna C8 (2) preparative column with a
gradient of water/acetonitrile containing 0.1% trifluoroacetic acid, then
lyophilized to produce the desired compounds as white powders.
Compound identity was confirmed via RP-HPLC-mass spectrometry.
hGLP-1 (7e36 amide) was purchased from Anaspec (Cat #: AS-
22463, Fremont, CA, USA). hGIP (1e42) was purchased from Anas-
pec (Cat #: AS-61226-1, Fremont, CA, USA).
2.3. Cell culture
HEK293T cells lacking endogenous GLP-1R and GIPR were cultured in
Dulbecco’s Modified Eagle Medium (DMEM, Cat #: 11995073, Life
Technologies, Carlsbad, CA, USA) with 10% heat-inactivated fetal
bovine serum (FBS, Cat #: 10500064, Life Technologies, Carlsbad, CA,
USA), 100 IU/mL of penicillin, and 100 mg/mL of streptomycin solution
(Pen-Strep, Cat #: P4333, SigmaeAldrich, St. Louis, MO, USA). Min6
cells were cultured in Dulbecco’s Modified Eagle Medium with 15%
heat-inactivated fetal bovine serum, 100 IU/mL of penicillin, 100 mg/
mL of streptomycin solution, 20 mM of HEPES, and 50 mM of b-
mercaptoethanol. All of the cells were maintained at 37 C in 5% CO2.
2.4. Ligand-induced BRET assay
The cells were seeded (700,000 cells/well) in 6-well plates and
incubated tow70% confluency in complete media supplemented with
10% FBS and 1% Pen-Strep. Twenty-four hours after seeding, over-
expression of target proteins was performed under transient trans-
fection conditions using Lipofectamine 2000 (Cat #: 11668019,
Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s pro-
tocol without including additional carrier DNA. Twenty-four hours after
transfection, the cells were washed with PBS, then detached and
resuspended in FluoroBrite phenol red-free complete media (Cat #:
A1896701, Life Technologies, Carlsbad, CA, USA) containing 5% FBS
and 2 mM of L-glutamine (Cat #: 25030081, Life Technologies,
Carlsbad, CA, USA). Then 100,000 cells/well were plated into poly-D-
lysine-coated (Cat #: P6403, SigmaeAldrich, St. Louis, MO, USA) 96-
well white polystyrene LumiNunc microplates (Cat #: 10072151,
Thermo Fisher Scientific, Waltham, MA, USA). After 24 h, the media
was replaced with PBS (Cat #: 10010056, Gibco, Carlsbad, CA, USA)
containing 10 mM of coelenterazine-h (Cat #: S2011, Promega,
Madison, WI, USA) or 1:500 NanoGlo (Cat #: N1110, Promega, Mad-
ison, WI, USA). BRET1 measurements were taken every 30 s for
2 min at 37 C using a PHERAstar FS multi-mode microplate reader
with 430e485 nm and 505e590 nm dual filters. Baseline mea-
surements were taken after 5 min of incubation with coelenterazine-h
or NanoGlo. The cells were then treated with a vehicle or the respective
agonists. The resulting ratiometric BRET signal between the interacting
fluorophore and lumiphore was normalized by subtracting the back-
ground ratio (505e590 nm emission over 430e485 nm) of thembH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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vehicle-treated wells with the matched agonist-treated wells produc-
ing a signal defined as the “ligand-induced BRET ratio” [25]. The
temporal data of the vehicle-corrected agonist measurement was then
normalized to the baseline reading of the same well. The first BRET
reading following treatment with agonist/vehicle was the subsequent
measurement after the zero time point. Positive or negative incre-
mental areas under the curves (þiAUC/-iAUC) were calculated where
noted. Each experiment was independently performed at least three
times, with at least two technical replicates for each group.
2.5. G-protein recruitment assay
Mini-G protein probes translocate to ligand-bound active receptors
retaining their specificity (Wan et al., 2018). To measure the ligand-
induced recruitment of the Gas, Gaq, Gai, and Ga12/13, 50 ng DNA
of the respective NLuc-tagged mini-G plasmid was co-transfected with
500 ng DNA of GLP-1R GFP or GIPR-GFP per well of a 6-well plate.
2.6. cAMP assay
CAMYEL, a cAMP sensor using YFP-Epac-RLuc [23] was utilized to
quantify cAMP accumulation with the temporal resolution. Then,
500 ng of CAMYEL DNA was co-transfected with 500 ng of DNA of
untagged GLP-1R or GIPR per well in a 6-well plate. The experiments
were performed in the absence of 3-isobutyl-1-methylxanthine (IBMX).
2.7. GPCR internalization assay
A GPCR internalization assay was established by measuring the loss of
baseline resonance energy transfer between an intracellular plasma
membrane marker Venus-KRAS and hGLP-1R-RLUC8 or hGIPR-RLUC8
[26]. Then, 500 ng of Venus-KRAS DNA and 300 ng of the respective
RLUC8-tagged GPCR DNA were used per well in a 6-well plate.
2.8. b-arrestin recruitment assay
Co-localization of b-arrestin1/2-RLUC8 with GLP-1R-GFP or GIPR-GFP
was assessed [27]. Fifty ng of b-arrestin1-RLUC8 or b-arrestin2-
RLUC8 DNA and 300 ng of GLP-1R-GFP or GIPR-GFP DNA were co-
transfected into each well in a 6-well plate.
2.9. Endosomal trafficking assay
GPCR endosomal trafficking [28] was assessed by measuring the
ligand-stimulated gain in resonance energy transfer between Venus-
Rab5/7/11 and hGLP-1R-RLUC8 or hGIPR-RLUC. Then, 100 ng of the
respective Venus-Rab subtype DNA and 100 ng of hGLP-1R-RLUC8 or
hGIPR-RLUC8 DNA were co-transfected into each well in a 6-well
plate.
2.10. Endosomal G-protein recruitment assay
Endosomal G-protein recruitment was assessed by bystander BRET via
GPCR-induced co-localization of Gas-NLuc with Venus-Rab5/7/11.
Then, 300 ng of GLP-1R-untagged or GIPR-untagged DNA, 500 ng
of Venus-Rab5/7/11 DNA, and 50 ng of Gas-NLuc DNA were co-
transfected per well in a 6-well plate.
2.11. HILO microscopy
HEK293T cells were seeded onto 24 mm coverslips (Cat #: 631e1584,
VWR, Radnor, PA, USA) and transfected with 500 ng of GLP-1R-GFP or
GIPR-GFP over 24 h. HILO image sequences were acquired with a
custom-built TIRF microscope (Cairn Research) based on an Eclipse
Ti2 (Nikon, Tokyo, Japan) equipped with an EMCCD camera (iXon Ultra,
Andor), a 488 nm diode laser, a hardware Perfect Focus System, aMOLECULAR METABOLISM 49 (2021) 101181  2021 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.comTIRF iLas2 module, and a 100 oil-immersion objective (NA 1.49,
Nikon). Coverslips were mounted onto metal imaging chambers with a
plastic seal and filled with imaging medium (HBSS supplemented with
10 mM of HEPES). The objective and samples were maintained at
37 C in a heated enclosure. Images were acquired on MetaMorph
software (Molecular Devices) using a frame exposure of 50e200 ms
with an image acquired before ligand stimulation and a subsequent
image taken every 30 s thereafter, up to 20 min. All of the images were
analyzed using ImageJ.
2.12. Data analysis
Data are represented as means  S.E.M. Each experiment was
independently conducted at least three times, each with at least two
technical replicates. Emax values were normalized to GLP-1 (7e36
amide) or GIP (1e42). Dose responses were fitted using non-linear
regression. pEC50 and EC50 values were calculated using GraphPad
Prism 8.0 (GraphPad, San Diego, CA, USA). Statistical analyses were
calculated in GraphPad 8.0 using one-way analysis of variance
(ANOVA) and corrected with Tukey’s or Bonferroni’s multiple com-
parison test. Differences are considered significant with an adjusted p
value < 0.05.
3. RESULTS
3.1. MAR709 and tirzepatide differed from GLP-1R and GIPR
mono-agonists in G protein recruitment
Ligand-induced (1 mM) capacity for receptor G protein recruitment was
assessed using bioluminescence resonance energy transfer (BRET)-
based technology in HEK293T cells transiently transfected with the
respective GFP-tagged receptors and mini-G constructs. The mole-
cules evaluated included the native ligands GLP-1 (7e36 amide) and
GIP (1e42), semaglutide (Novo Nordisk, Copenhagen, Denmark), the
GLP-1/GIP dual-agonists tirzepatide (Eli Lilly, Indianapolis, IN, USA) and
MAR709 (Novo Nordisk, Copenhagen, Denmark), and two molecules
(fatty acyl-GLP-1 and fatty acyl-GIP) that are derived from the MAR709
sequence but had been structurally modified via single- or double-
point mutations to only activate either GLP-1R or GIPR (Figure 1). A
table including the external company identifiers, in-text abbreviations,
and amino acid sequence structures of the agonists is available
(Supplementary Table 1).
In GLP-1Rþ HEK293T cells, GLP-1 (7e36 amide) strongly recruited
Gas and to a lesser extent Gaq, with no meaningful recruitment of Gai
and Ga12/13 (Figure 2AeD). GIP (1e42) and fatty acyl-GIP did not
stimulate G protein recruitment in GLP-1Rþ HEK293T cells, while
semaglutide and fatty acyl-GLP-1 elicited comparable responses
relative to GLP-1 (7e36 amide) (Figure 2AeD). Relative to the GLP-1
mono-agonists, both GLP-1/GIP dual-agonists showed a decreased
ability to recruit Gas and Gaq, however, MAR709 demonstrated a
higher capacity to recruit Gas and Gaq compared to tirzepatide
(Figure 2A,B). The chimeric structures of MAR709 and tirzepatide did
not additionally diversify the G-protein families recruited to the receptor
as evidenced by a lack of Gai and Ga12/13 recruitment (Figure 2AeD).
In GIPRþ HEK293T cells, native GIP (1e42) predominantly recruited Gas
without meaningful recruitment of Gaq, Gai, and Ga12/13 (Figure 2Ee
H). As expected, GLP-1 (7e36 amide), fatty acyl-GLP-1 and sem-
aglutide all showed negligible effects on G protein recruitment in the
absence of GLP-1R (Figure 2EeH). Relative to native GIP (1e42), Gas
recruitment following treatment with fatty acyl-GIP and tirzepatide was
comparable, but with MAR709 it slightly decreased (Figure 2E).an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 3
Figure 1: Schematic and structure of the tested GLP-1R and GIPR ligands. GLP-1R mono-agonists comprised of human GLP-1 (7e36 amide), semaglutide, and fatty acyl-
GLP-1 (a pharmacokinetically-matched His1 and Val10 mutant of MAR709) (left panel). GIPR mono-agonists include human GIP (1e42) and fatty acyl-GIP (a pharmacokinetically
matched Ile7 mutant of MAR709) (middle panel). GLP-1/GIP dual-agonist MAR709 and tirzepatide (right panel).
Figure 2: Ligand-induced G protein recruitment at GLP-1R and GIPR. Ligand-induced (1 mM) recruitment of Nluc-tagged Gas (A), Gaq (B), Gai (C), and Ga12/13 (D) to GFP-
tagged GLP-1R in HEK293T cells. Ligand-induced (1 mM) recruitment of Nluc-tagged Gas (E), Gaq (F), Gai (G), and Ga12/13 (H) with GFP-tagged GIPR
þ HEK293T cells. The positive
iAUC (þiAUC) representation of vehicle and baseline-corrected 30 min response to each agonist is expressed as mean  SEM. Bonferroni’s test, *p < 0.05, **p < 0.005, and
***p < 0.0005 using one-way ANOVA vs GLP-1 (7e36 amide) or GIP (1e42). Three independent experiments were performed with at least two technical replicates per group.
Original ArticleIn summary, the GLP-1 mono-agonists and GLP-1/GIP dual-agonists
primarily initiated Gas recruitment, and to a lesser extent Gaq, at the
GLP-1R and GIPR. In relation to the GLP-1 mono-agonists, both GLP-1/
GIP dual-agonists showed decreased Gas and Gaq recruitment in GLP-
1Rþ HEK293T cells. In GIPRþ cells, tirzepatide led to comparable
recruitment of Gas relative to native GIP while MAR709 showed a slight
decrease in Gas recruitment.4 MOLECULAR METABOLISM 49 (2021) 101181  2021 The Authors. Published by Elsevier G3.2. MAR709 and tirzepatide were partial agonists for Gas
recruitment at GLP-1R but full agonists for cAMP production
We next assessed concentration-response dependence in ligand-
induced Gas recruitment and evaluated how this capacity translated
to cAMP production. At all of the tested concentrations, semaglutide
and fatty acyl-GLP-1 showed comparable Gas recruitment relative to
native GLP-1 (7e36 amide) in GLP-1Rþ cells (Figure 3A). In line withmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
www.molecularmetabolism.com
Figure 3: Dose-dependent effects of ligands on Gas recruitment and cAMP production. Doseeresponse curves (A) and temporal resolution (1 mM stimulation) (B) of ligand-
induced BRET changes between Nluc-tagged Gas recruitment to GFP-tagged GLP-1R. Doseeresponse curves of ligand-induced cAMP production GLP-1R
þ HEK293T cells (C).
Doseeresponse curves (D) and temporal resolution (1 mM stimulation) (E) of ligand-induced Gas recruitment to the GIPR. Doseeresponse curves of ligand-induced cAMP
production GIPRþ HEK293T cells (F). þiAUC representation of vehicle and baseline-corrected 60 min (Gas recruitment) or 25 min (cAMP generation) temporal responses to each
agonist is expressed as mean  SEM. Three independent experiments were performed with at least two technical replicates per group.our previous data (Figure 2A), MAR709 and tirzepatide both acted as
partial agonists at the GLP-1R, stimulating a respective 59% and 31%
maximal Gas recruitment (Emax) relative to GLP-1 (7e36 amide)
(Figure 3A and Table 1). This partial agonism was independent of the
measurement time after drug exposure (Figure 3B). Interestingly,
despite a reduced Gas recruitment Emax, the dual-agonists did not
differ in cAMP Emax compared to the GLP-1 mono-agonists (Figure 3C
and Table 1). This was further validated with a CAMYEL sensor
saturation assay (Supplementary Figure 4A-C), with ligand responses
falling below the saturation limit of the sensor. Hence, despite partial
agonism at the level of G protein recruitment to GLP-1R, the dual-
agonists remained full agonists when considering cAMP generation.
In terms of potency, all of the agonists displayed similar cAMP pEC50
values except for tirzepatide, which was significantly decreased rela-
tive to GLP-1 (7e36 amide) (Figure 3C and Table 1).
In GIPRþ HEK293T cells, we observed a comparable potency and
efficacy for Gas recruitment upon treatment with fatty acyl-GIP and
both dual-agonists relative to native GIP (1e42) (Figure 3D and
Table 1), which was independent of the measurement time after drug
exposure (Figure 3E). MAR709 exhibited a slightly reduced efficacy at
the GIPR, stimulating 81% of the Gas recruitment Emax elicited by
native GIP (1e42) (Figure 3D and Table 1). For cAMP production, both
fatty acyl-GIP and MAR709 displayed a significantly superior pEC50
than that of GIP (1e42), while tirzepatide exhibited a significant 3-
fold reduction in potency (Figure 3F and Table 1). Collectively,
MAR709 and tirzepatide displayed unique agonism properties at their
target receptors, retaining full cAMP efficacy at both the GLP-1R and
GIPR despite relatively lower GLP-1R-specific Gas recruitment effi-
cacy and a slightly reduced relative potency of tirzepatide for cAMP
production at the GIP receptor.MOLECULAR METABOLISM 49 (2021) 101181  2021 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.com3.3. MAR709 and tirzepatide showed decreased receptor
internalization relative to GLP-1R and GIPR mono-agonists
We next assessed ligand-induced receptor internalization and the
recruitment of b-arrestin and Gaq. In hGLP-1R-Rluc8
þ HEK293T cells,
semaglutide and fatty acyl-GLP-1 showed similar receptor internali-
zation dynamics relative to GLP-1 (7e36 amide) (Figure 4A,B). How-
ever, both MAR709 and tirzepatide showed strikingly decreased
receptor internalization compared to the tested GLP-1R mono-agonists
(Figure 4A,B). Relative to GLP-1 (7e36 amide), the maximal ligand-
induced GLP-1R internalization (Emax) of MAR709 and tirzepatide
was 51% and 13%, respectively (Figure 4A,B and Table 1). Likewise,
decreased internalization of GLP-1R was also observed upon treatment
of hGLP-1R-Rluc8þ Min6 cells with MAR709 and tirzepatide relative to
GLP-1 (7e36 amide) and GLP-1 mono-agonists (Supplementary
Figure 5A-C). No significant differences were observed in the pEC50
values of the tested ligands in HEK293T cells. Decreased receptor
internalization mediated by MAR709 and tirzepatide was also
confirmed using live cell HILO microscopy in HEK293T cells expressing
GLP-1R-GFP (Figure 4C). While treatment with GLP-1 (7e36 amide)
and semaglutide initiated rapid internalization of GLP-1R-GFP,
MAR709 and tirzepatide showed the persistent presence of the
ligandereceptor complex at the plasma membrane with strikingly less
trafficking into the cytosol (Figure 4C). These data collectively
demonstrated that MAR709 and tirzepatide differed from the GLP-1R
mono-agonists in that they showed prolonged receptor presence at
the cell surface and reduced receptor internalization.
GLP-1R recruitment of b-arrestin 1/2 (b-arr1/2) has been shown to
influence receptor trafficking and enhance extracellular signal-
regulated kinase 1/2 (ERK1/2) signaling [29]. In GLP-1Rþ HEK293T
cells, semaglutide stimulated 67% and 78% of the b-arr1 and b-arr2an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 5
Table 1 e Maximal (Emax) drug effects and affinities at the GLP-1R or GIPR target receptors. Data were generated in HEK293T cells transiently transfe-
cted to express GLP-1R or GIPR. Emax, pEC50, and EC50 values were generated from doseeresponse values fitted to sigmoidal curves using a three-parameter
non-linear logistic regression. The Emax is the maximal response elicited by an agonist and is expressed as % of the maximum response of GLP-1 (7e36 amide)
or GIP (1e42). The EC50 is the molar concentration in which an agonist produced half of the maximal response. The pEC50 is the negative logarithm of the
EC50. Values are given for Gas recruitment, cAMP accumulation, receptor internalization, b-arrestin
1/2, and Gaq recruitment at the GLP-1R and the GIPR. All of
the values were derived from the iAUC of a temporal response for each concentration/agonist and are expressed as mean  SEM from at least 3 independent
experiments with at least two technical replicates per group. Statistical significance was determined using one-way ANOVA and corrected with Bonferroni’s
multiple comparisons test. */#/yp < 0.05. * vs GLP-1 (7e36 amide) or GIP (1e42).# vs semaglutide. y vs fatty acyl-GLP-1 or fatty acyl-GIP. NA ¼ no agonism
significantly different than zero observed at 1 mM stimulation. Bold red ¼ with significant non-zero agonism at 1 mM stimulation but incomplete curve fit, last
value at 10 mM used.
Figure 4: Ligand-induced GLP-1R internalization. Doseeresponse curves (A) and temporal resolution (1 mM stimulation) (B) of ligand-induced hGLP-1-Rluc8 internalization as
measured by loss of BRET with plasma membrane marker Venus-KRAS. Live HILO imaging of GLP-1R-GFP internalization in HEK293T cells at baseline and approximately 15 min
after drug (1 mM) treatment (representative image from n ¼ 4 experiments) (C). Doseeresponse curves for b-arrestin 1-Rluc8 (D), b-arrestin 2-Rluc8 (E), and Gaq-Nluc
recruitment (F) to GLP-1R-GFP. The þ iAUC representation of vehicle and baseline-corrected 60 min (GLP-1R internalization and Gaq recruitment) or 30 min (b-arrestin1/2
recruitment) temporal response to each agonist is expressed as mean  SEM. Three independent experiments were performed with at least two technical replicates per group.
Original Articlerecruitment Emax elicited by GLP-1 (7e36 amide), while fatty acyl-GLP-
1 elicited a slightly reduced 86% of b-arr2 (Figure 3D,E and Table 1). A
pronounced reduction in b-arrestin recruitment efficacy with the dual-
agonists was observed, in which treatment with MAR709 led to 35%6 MOLECULAR METABOLISM 49 (2021) 101181  2021 The Authors. Published by Elsevier Gand 24% of the GLP-1 (7e36 amide) b-arr1 and b-arr2 recruitment
Emax (Figure 4D,E and Table 1), while no measurable response for
either b-arr1 or b-arr2 was seen with tirzepatide (Figure 4D,E and
Table 1).mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
www.molecularmetabolism.com
Figure 5: Ligand-induced GIPR internalization. Doseeresponse curves (A) and temporal resolution (1 mM stimulation) (B) of ligand-induced hGIPR-Rluc8 internalization. Live
HILO imaging of GIPR-GFP internalization in HEK293T cells at baseline and approximately 15 min after drug (1 mM) treatment (C). Doseeresponse curves for b-arrestin 2-Rluc8 (D)
and Gaq-Nluc recruitment (E). The þ iAUC representation of vehicle and baseline-corrected 20 min (GIPR internalization), 30 min (b-arrestin1/2 recruitment), or 60 min (Gaq
recruitment) temporal response to each agonist is expressed as mean  SEM. Three independent experiments were performed with at least two technical replicates per group.GLP-1R recruitment of Gaq has been proposed to regulate GLP-1R
internalization via an ERK1/2 pathway [30]. In line with this data and
our demonstration of decreased GLP-1R internalization upon treatment
with MAR709 and tirzepatide (Figure 4AeC), we saw a less efficacious
Gaq recruitment response to the GLP-1R upon treatment with MAR709
and tirzepatide, in which 48% and 17% of the GLP-1 (7e36 amide)
Emax was achieved, respectively (Figure 4F and Table 1).
In hGIPRþ HEK293T cells, we observed sustained receptor internali-
zation induced by GIP (1e42) but no meaningful internalization
following treatment with either fatty acyl-GIP, the GLP-1 mono-ago-
nists, or the dual-agonists (Figure 5A,B). In detail, MAR709 and tir-
zepatide stimulated 4% and 18% of the GIP (1e42) receptor
internalization Emax (Figure 5A,B and Table 1). Reduced capacity of the
dual-agonists for GIPR internalization was also confirmed visually
through live-cell microscopy. Fifteen minutes after compound
administration, GIP (1e42) showed a high dissolution of the GIPR-GFP-
defined plasma membrane border with greater punctate structure
formation in the cytosol, while neither MAR709 nor tirzepatide evoked
a similar dynamic (Figure 5C).
Unlike b-arr2, b-arr1 has been shown to lack a functional role in GIPR
internalization and trafficking [31]. Relative to GIP (1e42) at the
maximal concentration of 10 mM, a 36% and 35% b-arr2 recruitment
response was observed in cells treated with MAR709 or tirzepatide
(Figure 5D and Table 1). A true comparison between GIPR-b-arr2
agonist Emax was not possible due to an incomplete curve fit for GIP
(1e42). However, these data collectively suggested that reduced b-
arrestin 2 recruitment by the dual-agonists may have had a functional
correlation in the observed reduction in GIPR internalization or traf-
ficking by these molecules.
Relative to the Gaq recruitment Emax for GIP (1e42), treatment with fatty
acyl-GIP displayed a similar efficacy while MAR709 and tirzepatide
exhibited 68% and 85% of themaximal response (Figure 5E and Table 1).
In summary, these data showed that MAR709 and tirzepatide both
differed from the native peptides, semaglutide, and the PK-matchedMOLECULAR METABOLISM 49 (2021) 101181  2021 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.comreceptor mono-agonists (fatty acyl-GIP and fatty acyl-GLP-1) in that
they showed reduced internalization and decreased b-arrestin and Gaq
recruitment at both target receptors.
3.4. MAR709 and tirzepatide induced differential endosomal
receptor trafficking relative to GLP-1R and GIPR mono-agonists
We next evaluated endosomal trafficking of the ligand-receptor com-
plexes by assessing the co-localization of hGLP-1R-Rluc8 with Venus-
tagged markers indicative of early endosomes (Rab5), late endosomes
(Rab7), or recycling endosomes (Rab11) (Supplementary Figure 1).
Consistent with our previous results showing decreased internalization
of GLP-1R and GIPR by the dual-agonists (Figure 4AeC and
Figure 5AeC), 1 mM stimulation with MAR709 or tirzepatide resulted in
68% and 13% of the total GLP-1R Rab5 co-localization elicited by GLP-
1 (7e36 amide) (Figure 6AeC). Similar patterns were also observed
when assessing total Gas recruitment to GLP-1R
þ Rab5þ endosomes
(Supplementary Figure 2A-C). No difference in Rab5 co-localization
was observed between GLP-1 (7e36 amide), semaglutide, and fatty
acyl-GLP-1 (Figure 6AeC). In a hGLP-1R-Rluc8þ min6 b cell model,
tirzepatide likewise stimulated reduced co-localization of GLP-1R into
Rab5þ endosomes compared to GLP-1 (7e36 amide) and GLP-1
mono-agonists (Supplementary Figure 5D-F). Within HEK293T cells,
co-localization of GLP-1R with Rab7 positive (late) endosomes was
reduced, with MAR709 and tirzepatide stimulating 62% and 24% of
the response of GLP-1 (7e36 amide) (Figure 6DeF). This pattern was
replicated in ligand-induced Gas recruitment to GLP-1R
þ Rab7þ
endosomes (Supplementary Figure 2D-F). Notably, differences in GLP-
1R co-localization with Rab11-positive recycling endosomes were
insignificant between treatments of MAR709 and GLP-1 (7e36
amide), but treatment with tirzepatide decreased by 54% (Figure 6Ge
I). Despite substantial Gas recruitment to Rab11
þ endosomes, endo-
somal Gas recruitment by MAR709 was significantly reduced
compared to GLP-1 (7e36 amide) (Supplementary Figure 2F-I).
Regarding the Min6 cell model, due to either a lack of BRET signals oran open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 7
Figure 6: Ligand-induced GLP-1R endosomal trafficking. Ligand-induced co-localization of GLP-1R-Rluc8 with Venus-Rab5 early endosomes (AeC), Venus-Rab7 late
endosomes (DeF), and Venus-Rab11 recycling endosomes (GeI). The þ iAUC representation of vehicle and baseline-corrected temporal response to each agonist is expressed as
mean  SEM. Bonferroni’s test, *p < 0.05, **p < 0.005, and ***p < 0.0005 using one-way ANOVA vs GLP-1 (7e36 amide). Six independent experiments were performed with
at least two technical replicates per group.
Original Articlethe requirement for improved detection sensitivity, replication of
ligand-induced GLP-1R co-localization with Rab7-and Rab11-positive
endosomes was not observable for any agonist (Supplementary
Figure 5G-J). In HEK293T cells, the general agonist relationship be-
tween the AUC of GLP-1R endosomal co-localization and endosomal G-
protein recruitment was positively linear, in which greater endosomal
trafficking was associated with greater Gas recruitment to the endo-
somal sub-compartment (Supplementary Figure 6A-C). In summary,
these data indicated that MAR709 not only induced less GLP-1R co-
localization into early and late endosomes but also comparably
incorporated GLP-1R into Rab11þ recycling endosomes to that of GLP-
1 (7e36 amide) and semaglutide in HEK293T cells.
In GIPRþ HEK293T cells, GIPR co-localization into Rab5þ endosomes
was similar upon treatment with GIP (1e42), fatty acyl-GIP, and tir-
zepatide; however, MAR709 achieved approximately 66% of this
response (Figure 7A,B). This pattern was also seen in Gas recruitment
to Rab5þ endosomes. No meaningful co-localization was detected
with GIPR at either Rab7 or Rab11 (Figure 7CeF). The lack of receptor8 MOLECULAR METABOLISM 49 (2021) 101181  2021 The Authors. Published by Elsevier Gco-localization with Rab7þ and Rab11þ endosomes was similarly
associated with a lack of endosomal Gas recruitment (Supplementary
Figure 3D-H). Discrepancies between GIPR Rab5þ co-localization and
the lack of GIP receptor internalization by the dual-agonists likely re-
flected methodological differences and/or lack of Rab5þ early endo-
some scission from the plasma membrane.
4. DISCUSSION
Our data showed that the GLP-1/GIP dual-agonists MAR709 and tir-
zepatide differed from the GLP-1R and GIPR mono-agonists in terms of
G protein recruitment, target receptor internalization, and endosomal
trafficking. Although both dual-agonists showed delayed internalization
at both target receptors, MAR709 but not tirzepatide induced com-
parable GLP-1R accumulation into Rab11þ recycling endosomes to
that of GLP-1 (7e36 amide) and semaglutide.
Both MAR709 and tirzepatide exhibited reduced Gas recruitment to the
GLP-1R relative to GLP-1 (7e36 amide) while retaining full-agonistmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
www.molecularmetabolism.com
Figure 7: Ligand-induced GIPR endosomal trafficking. Ligand-induced co-localization of GIPR with Venus-Rab5þ early endosomes (A and B), Venus-Rab7þ late endosomes (C
and D), and Venus-Rab11þ recycling endosomes (E and F). The þ iAUC representation of vehicle and baseline-corrected temporal response to each agonist is expressed as
mean  SEM. Bonferroni’s test, *p < 0.05, **p < 0.005, and ***p < 0.0005 using one-way ANOVA vs GIP (1e42). Six independent experiments were performed with at least
two technical replicates per group.capacity for cAMP, likely an advantageous effect of signal amplification
systems. Similarly, both MAR709 and tirzepatide evidenced full ago-
nism for cAMP at the GIPR, but only MAR709 displayed characteristics
of partial agonism with a slight reduction in Gas recruitment efficacy.
These data together were in line with previously established reports
[19]. Since MAR709 and tirzepatide showed 100% sequence homol-
ogy at positions 1e12, the observed differences between MAR709 and
tirzepatide apparently resulted from sequence substitutions at posi-
tions 13e27 of the peptides or from the size and location of fatty
acylation. The aforementioned differences in total and endosomal Gas
recruitment may play a role in the endosomal sorting of the internalized
receptor to Rab7þ/lysosomal pathways [32].
GLP-1R internalization is primarily caveolin-1/dynamin dependent [33],
mediated by Gaq signaling [30], and does not require but is influenced
by b-arrestin [16,34]. GLP-1R internalization has been linked to theMOLECULAR METABOLISM 49 (2021) 101181  2021 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.comdegree of cellular desensitization and insulin secretion in vitro [16,35].
Tirzepatide has previously been shown to elicit reduced GLP-1R
internalization relative to native GLP-1 [36]. Whether this effect also
holds true for other dual-agonists has yet to be demonstrated. Both
dual-agonists evaluated herein retained a higher presence of GLP-1R
at the plasma membrane relative to the tested GLP-1R mono-agonists
and similarly displayed corresponding partial agonism for b-arrestin 1,
b-arrestin 2, and Gaq recruitment to the GLP-1R. A Phe1 substitution
within an exendin-4 sequence has previously been described to reduce
GLP-1R internalization and b-arrestin recruitment [16]. In line with
this, reduced internalization is also observed with a (phenolic) Tyr1
present in the MAR709 and tirzepatide amino acid sequences.
Both dual-agonists showed minimal GIPR internalization relative to GIP
(1e42). Yet, both GIP (1e42) and tirzepatide elicited equal GIPR
incorporation into Rab5þ early endosomes. Reasons for thean open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 9
Original Articlediscrepancy might have originated in the methodology of how inter-
nalization was assessed.
Ligand-induced GLP-1R endosomal trafficking has not yet been fully
elucidated. We showed that MAR709 did not differ from GLP-1 (7e36
amide) and semaglutide in terms of eliciting GLP-1R co-localization
with Rab11þ recycling endosomes. Whether this was a consequence
primarily of internalized receptor diverting into recycling pathways or
whether increased Rab11 co-localization induced by MAR709 was
supplemented with recruitment of GLP-1R from the biosynthetic
pathway has yet to be established. Given the low rate of GLP-1R
internalization and incorporation into Rab5þ and Rab7þ endo-
somes, MAR709’s high capacity for Rab11þ co-localization and its
biased signaling profile demonstrated unique spatiotemporal phar-
macology at the GLP-1R that may facilitate potential attributes of
cellular sensitization. A caveat to the receptor trafficking experiments
was the limited potential for aberrant Venus-Rab localization into non-
specific endosomal compartments occurring from over-expression
associated changes in Rab trafficking patterns. Additionally, trans-
ferability of these findings to physiologically relevant b cells was
restricted to the min6 b cell model, and hence represents a limitation
of this work.
Despite favoring GIPR over the GLP-1R, tirzepatide showed compa-
rable efficacy and potency relative to MAR709 at multiple signaling
pathways connected to the GIPR, with the exception of cAMP pEC50 in
which MAR709 exhibited higher potency. At the GLP-1R, MAR709
displayed higher Gas/Gaq signaling, receptor internalization, and b-
arrestin recruitment relative to tirzepatide despite still acting as a
partial agonist in each of these categories. In addition, MAR709 elicited
a disproportional incorporation of the GLP-1R into Rab11þ recycling
endosomes. Collectively, our data showed that MAR709 and tirzepa-
tide differed from the tested receptor agonists in G protein recruitment,
receptor internalization, and endosomal trafficking, which together
supports the hypothesis that biased agonism of these molecules might
contribute to their beneficial metabolic action profile.
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